# Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

> **NCT07160205** · PHASE2,PHASE3 · RECRUITING · sponsor: **Restem, LLC.** · enrollment: 40 (estimated)

## Conditions studied

- Idiopathic Inflammatory Myositis (IIM)
- DERMATOMYOSITIS OR POLYMYOSITIS

## Interventions

- **BIOLOGICAL:** ULSC (1.5 x 10^8 cells/dose)
- **BIOLOGICAL:** Placebo (no cells)

## Key facts

- **NCT ID:** NCT07160205
- **Lead sponsor:** Restem, LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-06
- **Primary completion:** 2028-09
- **Final completion:** 2029-08
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07160205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07160205, "Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07160205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*